The Utility of Point of Care Biomarkers to Detect Cardiotoxicity during Anthracycline Chemotherapy: A Feasibility Study

Highlights • Cardiac biomarkers, specifically BNP, can be part of an effective screening strategy for Anthracycline-related cardiotoxicity • In this study, LVEF does not appear to be adequate for the detection of cardiotoxicity • BNP may allow us to direct cardioprotective therapy. More analysis wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiac failure 2016-06, Vol.22 (6), p.433-438
Hauptverfasser:	Lenihan, Daniel J., MD, Stevens, Patrick L, MD, Massey, Mona, RN, BSN, Plana, Juan Carlos, MD, Araujo, Dejka M, MD, Fanale, Michelle A, MD, Fayad, Luis E, MD, Fisch, Michael J, MD, MPH, Yeh, Edward TH, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anthracycline cardiotoxicity Anthracyclines - adverse effects Anthracyclines - therapeutic use biomarkers Biomarkers - blood cardioprotection Cardiotoxicity - blood Cardiotoxicity - diagnosis Cardiovascular Feasibility Studies Female Heart Diseases - blood Heart Diseases - chemically induced Humans Male Middle Aged Natriuretic Peptide, Brain - blood Neoplasms - blood Neoplasms - drug therapy Point-of-Care Systems Troponin I - blood Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Cardiac biomarkers, specifically BNP, can be part of an effective screening strategy for Anthracycline-related cardiotoxicity • In this study, LVEF does not appear to be adequate for the detection of cardiotoxicity • BNP may allow us to direct cardioprotective therapy. More analysis with high sensitivity troponin is needed
ISSN:	1071-9164 1532-8414
DOI:	10.1016/j.cardfail.2016.04.003